TBX21 and neoplasm: TBX21 expression was markedly reduced in EpCAM+ regions of sh-TBX21 tumors, whereas no significant difference was observed in CD3+ immune cell regions, indicating tumor cell–specific knockdown efficiency (Figure 4A).